Experimental treatments for asthma

Anthony A. Floreani, Stephen Israel Rennard

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

There has been increased recognition of the importance of inflammatory cells and their products in the pathogenesis of asthma. From this recognition has evolved a number of new approaches to treat the various components of the asthmatic inflammatory response. Nonselective anti-inflammatory agents such as cyclosporine and gold appear to decrease symptoms and allow a steroid-sparing effect in many cases, though side effects from cyclosporine often necessitate dose reduction. Novel oral compounds as the 5-lipoxygenase inhibitors have been effective in controlling asthma symptoms triggered by various stimuli, and the cysteinyl leukotriene receptor antagonists have shown promise in this regard as well. Neurokinin antagonists, inhaled loop diuretics, and lidocaine may play significant roles in asthma therapy through inhibition of neurogenic inflammation and possibly mast cell function. Inhibition of mast cell products by existing drugs such as heparin or the development of specific inhibitors of mast cell tryptase may also be effective agents, as are selective phosphodiesterase inhibitors, which appear to have anti-inflammatory properties. Finally, specific cytokine antagonists, agonists, inhibitors of T-cell function, selective inducible nitric oxide synthase inhibitors, and even gene-directed strategies may provide not only insights into the pathogenesis of asthma but also novel therapeutic approaches to treat the inflammation in this disease.

Original languageEnglish (US)
Pages (from-to)30-41
Number of pages12
JournalCurrent Opinion in Pulmonary Medicine
Volume3
Issue number1
DOIs
StatePublished - Jan 1 1997

Fingerprint

Asthma
Mast Cells
Cyclosporine
Anti-Inflammatory Agents
Neurogenic Inflammation
Sodium Potassium Chloride Symporter Inhibitors
Leukotriene Antagonists
Tryptases
Lipoxygenase Inhibitors
Phosphodiesterase Inhibitors
Nitric Oxide Synthase Type II
Lidocaine
Gold
Heparin
Steroids
Cytokines
Inflammation
T-Lymphocytes
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Experimental treatments for asthma. / Floreani, Anthony A.; Rennard, Stephen Israel.

In: Current Opinion in Pulmonary Medicine, Vol. 3, No. 1, 01.01.1997, p. 30-41.

Research output: Contribution to journalArticle

Floreani, Anthony A. ; Rennard, Stephen Israel. / Experimental treatments for asthma. In: Current Opinion in Pulmonary Medicine. 1997 ; Vol. 3, No. 1. pp. 30-41.
@article{b0a87474e2f1478182ae004ef629e064,
title = "Experimental treatments for asthma",
abstract = "There has been increased recognition of the importance of inflammatory cells and their products in the pathogenesis of asthma. From this recognition has evolved a number of new approaches to treat the various components of the asthmatic inflammatory response. Nonselective anti-inflammatory agents such as cyclosporine and gold appear to decrease symptoms and allow a steroid-sparing effect in many cases, though side effects from cyclosporine often necessitate dose reduction. Novel oral compounds as the 5-lipoxygenase inhibitors have been effective in controlling asthma symptoms triggered by various stimuli, and the cysteinyl leukotriene receptor antagonists have shown promise in this regard as well. Neurokinin antagonists, inhaled loop diuretics, and lidocaine may play significant roles in asthma therapy through inhibition of neurogenic inflammation and possibly mast cell function. Inhibition of mast cell products by existing drugs such as heparin or the development of specific inhibitors of mast cell tryptase may also be effective agents, as are selective phosphodiesterase inhibitors, which appear to have anti-inflammatory properties. Finally, specific cytokine antagonists, agonists, inhibitors of T-cell function, selective inducible nitric oxide synthase inhibitors, and even gene-directed strategies may provide not only insights into the pathogenesis of asthma but also novel therapeutic approaches to treat the inflammation in this disease.",
author = "Floreani, {Anthony A.} and Rennard, {Stephen Israel}",
year = "1997",
month = "1",
day = "1",
doi = "10.1097/00063198-199701000-00006",
language = "English (US)",
volume = "3",
pages = "30--41",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Experimental treatments for asthma

AU - Floreani, Anthony A.

AU - Rennard, Stephen Israel

PY - 1997/1/1

Y1 - 1997/1/1

N2 - There has been increased recognition of the importance of inflammatory cells and their products in the pathogenesis of asthma. From this recognition has evolved a number of new approaches to treat the various components of the asthmatic inflammatory response. Nonselective anti-inflammatory agents such as cyclosporine and gold appear to decrease symptoms and allow a steroid-sparing effect in many cases, though side effects from cyclosporine often necessitate dose reduction. Novel oral compounds as the 5-lipoxygenase inhibitors have been effective in controlling asthma symptoms triggered by various stimuli, and the cysteinyl leukotriene receptor antagonists have shown promise in this regard as well. Neurokinin antagonists, inhaled loop diuretics, and lidocaine may play significant roles in asthma therapy through inhibition of neurogenic inflammation and possibly mast cell function. Inhibition of mast cell products by existing drugs such as heparin or the development of specific inhibitors of mast cell tryptase may also be effective agents, as are selective phosphodiesterase inhibitors, which appear to have anti-inflammatory properties. Finally, specific cytokine antagonists, agonists, inhibitors of T-cell function, selective inducible nitric oxide synthase inhibitors, and even gene-directed strategies may provide not only insights into the pathogenesis of asthma but also novel therapeutic approaches to treat the inflammation in this disease.

AB - There has been increased recognition of the importance of inflammatory cells and their products in the pathogenesis of asthma. From this recognition has evolved a number of new approaches to treat the various components of the asthmatic inflammatory response. Nonselective anti-inflammatory agents such as cyclosporine and gold appear to decrease symptoms and allow a steroid-sparing effect in many cases, though side effects from cyclosporine often necessitate dose reduction. Novel oral compounds as the 5-lipoxygenase inhibitors have been effective in controlling asthma symptoms triggered by various stimuli, and the cysteinyl leukotriene receptor antagonists have shown promise in this regard as well. Neurokinin antagonists, inhaled loop diuretics, and lidocaine may play significant roles in asthma therapy through inhibition of neurogenic inflammation and possibly mast cell function. Inhibition of mast cell products by existing drugs such as heparin or the development of specific inhibitors of mast cell tryptase may also be effective agents, as are selective phosphodiesterase inhibitors, which appear to have anti-inflammatory properties. Finally, specific cytokine antagonists, agonists, inhibitors of T-cell function, selective inducible nitric oxide synthase inhibitors, and even gene-directed strategies may provide not only insights into the pathogenesis of asthma but also novel therapeutic approaches to treat the inflammation in this disease.

UR - http://www.scopus.com/inward/record.url?scp=0030640238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030640238&partnerID=8YFLogxK

U2 - 10.1097/00063198-199701000-00006

DO - 10.1097/00063198-199701000-00006

M3 - Article

VL - 3

SP - 30

EP - 41

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 1

ER -